| meta-analysis | Q815382 |
| review article | Q7318358 |
| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2016PLoSO..1166833W |
| P356 | DOI | 10.1371/JOURNAL.PONE.0166833 |
| P8608 | Fatcat ID | release_gtalzrmwzfd23jbvmr7zxwztii |
| P932 | PMC publication ID | 5119789 |
| P698 | PubMed publication ID | 27875559 |
| P2093 | author name string | Ting Liu | |
| Hui Mao | |||
| Zhu Lan | |||
| Fa-Ping Wang | |||
| Su-Yun Li | |||
| P2860 | cites work | Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. | Q49032278 |
| Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study | Q51026334 | ||
| Determining a minimal important change in a disease-specific Quality of Life Questionnaire | Q51136958 | ||
| A Phase 2a Study of Benralizumab for Patients with Eosinophilic Asthma in South Korea and Japan | Q51531321 | ||
| Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study | Q51534265 | ||
| Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma | Q51699006 | ||
| A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma | Q53176283 | ||
| Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. | Q55034563 | ||
| A re-analysis of the Cochrane Library data: the dangers of unobserved heterogeneity in meta-analyses | Q21559581 | ||
| Mepolizumab versus placebo for asthma | Q24186306 | ||
| Bronchial thermoplasty for moderate or severe persistent asthma in adults | Q24198119 | ||
| Purified interleukin 5 supports the terminal differentiation and proliferation of murine eosinophilic precursors | Q24682536 | ||
| The past, present, and future of monoclonal antibodies to IL-5 and eosinophilic asthma: a review | Q26775861 | ||
| Targeted anti-inflammatory therapeutics in asthma and chronic obstructive lung disease | Q26786229 | ||
| Emerging therapeutic options for the treatment of patients with symptomatic asthma | Q26800791 | ||
| Quantifying heterogeneity in a meta-analysis | Q27860672 | ||
| Reslizumab for Poorly Controlled, Eosinophilic Asthma | Q29040017 | ||
| The global burden of asthma: executive summary of the GINA Dissemination Committee report | Q29614904 | ||
| Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia | Q34230967 | ||
| Global strategy for asthma management and prevention: GINA executive summary. | Q34731997 | ||
| Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics | Q36001230 | ||
| A simulation study comparing properties of heterogeneity measures in meta-analyses | Q36601029 | ||
| Uncertainty in heterogeneity estimates in meta-analyses | Q36987539 | ||
| IL-5 and eosinophilia. | Q37176808 | ||
| Mepolizumab and exacerbations of refractory eosinophilic asthma | Q37711391 | ||
| Anti-interleukin-5 therapy in severe asthma | Q38133493 | ||
| Update on reslizumab for eosinophilic asthma | Q38587334 | ||
| Targeting the interleukin pathway in the treatment of asthma | Q38588854 | ||
| Emerging monoclonal antibodies as targeted innovative therapeutic approaches to asthma. | Q38616563 | ||
| A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthma | Q39090432 | ||
| Efficacy of Anti-Interleukin-5 Therapy with Mepolizumab in Patients with Asthma: A Meta-Analysis of Randomized Placebo-Controlled Trials | Q39353794 | ||
| Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial | Q39408906 | ||
| Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies | Q39768068 | ||
| Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials | Q41452053 | ||
| Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts | Q45294119 | ||
| Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial | Q45297326 | ||
| Mepolizumab for prednisone-dependent asthma with sputum eosinophilia | Q46098864 | ||
| Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial | Q47249808 | ||
| Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions | Q47890299 | ||
| Mepolizumab treatment in patients with severe eosinophilic asthma | Q48065984 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | asthma | Q35869 |
| peptide | Q172847 | ||
| globulins | Q321710 | ||
| monoclonal antibody | Q422248 | ||
| blood proteins | Q425056 | ||
| meta-analysis | Q815382 | ||
| systematic review | Q1504425 | ||
| quality of life | Q13100823 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | e0166833 | |
| P577 | publication date | 2016-11-22 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Efficacy and Safety of Anti-Interleukin-5 Therapy in Patients with Asthma: A Systematic Review and Meta-Analysis | |
| P478 | volume | 11 |
| Q92401162 | Adverse events of benralizumab in moderate to severe eosinophilic asthma: A meta-analysis |
| Q47551081 | Anti-IL5 therapies for asthma. |
| Q92756237 | Asthma and Chronic Rhinosinusitis: Diagnosis and Medical Management |
| Q39226704 | Clinical management of severe therapy-resistant asthma |
| Q49722360 | Cutaneous Manifestations of Reactions to Biologics |
| Q64113098 | Efficacy and steroid-sparing effect of benralizumab: has it an advantage over its competitors? |
| Q52646644 | Efficacy and tolerability of short-term duloxetine treatment in adults with generalized anxiety disorder: A meta-analysis. |
| Q55082118 | Health care resource utilization and characteristics of patients with eosinophilic asthma in secondary health care in Finland. |
| Q47555559 | Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma |
| Q38661881 | Reslizumab in the treatment of inadequately controlled asthma in adults and adolescents with elevated blood eosinophils: clinical trial evidence and future prospects |
| Q58778332 | Resolution of chronic inflammatory disease: universal and tissue-specific concepts |
| Q42370782 | Short-term efficacy and tolerability of venlafaxine extended release in adults with generalized anxiety disorder without depression: A meta-analysis |
| Q52571066 | Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma |
Search more.